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Abstract 
 
This study aimed to monitor estrous cycle 
parameters of a human granulocyte colony-stimulating 
factor (hG-CSF)-transgenic founder female goat and to 
perform superovulation and embryo recovery (surgical 
or transcervical method) for further transfer to recipients 
to quickly obtain offspring. Two experiments were 
performed using a transgenic (TF) and a non-transgenic 
(NTF) female. In experiment 1, three estrous cycles 
were monitored for the following parameters: estrus 
behavior, progesterone concentration and ovarian 
activity. In experiment 2, two superovulation/embryo 
recovery sessions were performed and the recovered 
embryos were transferred to previously prepared 
recipients. Data were compared by either t test or Fisher's 
exact test. The mean interval between natural estrus was 
20.7 ± 0.6 and 19.7 ± 0.6 (P > 0.05) days for the TF and 
NTF, respectively. Progesterone concentrations and 
ovarian activity were normal and similar between goats. 
The ovulation rate was similar between TF and NTF 
(12.0 ± 1.4 vs. 18.0 ± 4.2 CL; P > 0.05). No significant 
differences in embryo recovery rate (P > 0.05) were 
observed between the surgical and transcervical 
methods for TF (69.2 vs. 72.7%) or NTF (100.0 vs. 
86.7%). Sixteen embryos from the TF were transferred 
to recipients, and eight kids were born. Among these 
kids, the transgene was identified in three (two males 
and one female), resulting in a transgenesis rate of 
37.5%. In summary, the TF is a true founder, since she 
proved fertility and capacity of transmitting the hG-CSF 
transgene to progeny, suggesting that the analyzed 
reproductive traits were not compromised by the 
presence of the transgene. 
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superovulation, transgenesis. 
 
Introduction 
 
Gene pharming entails the production of 
recombinant, pharmaceutically active human proteins, 
mainly in the mammary gland of transgenic animals. 
Mammalian bioreactors have become an alternative to 
conventional systems due to the possibility of producing 
recombinant proteins on a large scale, the ability to 
obtain correct post-translational modifications and the 
established methods for extracting and purifying the 
respective protein (Kues and Niemann, 2004). In this 
context, goats represent an excellent transgenesis model 
when considering factors such as volume of milk 
produced per lactation, reproductive traits and the lower 
investment and maintenance costs compared to cattle 
(Baldassarre and Karatzas, 2004). 
Several recombinant proteins, mainly human, 
have been produced, purified and characterized from 
transgenic goats (reviewed in Moura et al., 2011). 
Currently, human antithrombin III produced by 
transgenic goats is the only recombinant protein from an 
animal bioreactor that has been approved for clinical use 
in Europe (Schmidt, 2006) and in the USA (Kling, 
2009). Thus, the transgenic technology was validated 
using a goat model as a viable alternative method for the 
production of recombinant pharmaceutical proteins. 
The recombinant proteins produced for 
pharmaceutical use include human granulocyte colony-
stimulating factor (hG-CSF), a hematopoietic cytokine 
that promotes the proliferation and differentiation of 
neutrophil precursors and the activation of mature 
neutrophils. This protein is widely used in different 
forms of neutropenia, chemotherapeutically induced 
leukopenia and mobilization of progenitor cells for 
autologous or allogenic transplants (Welte et al., 1996). 
In addition, hG-CSF has been investigated as a 
neuroprotective agent in cases of stroke (Solaroglu et 
al., 2006) and myocardial infarction (Harada et al., 
2005).  
Due to the importance of this recombinant 
protein in human medicine, our group began a program 
to produce hG-CSF-transgenic goats using pronuclear 
microinjection. Two transgenic founders were obtained 
(a male and a female), and the female expressed hG-
CSF in quantities sufficient for commercial use (Freitas 
et al., 2012). After obtaining a transgenic founder goat, 
it is imperative to investigate and characterize its 
feasibility as a potential bioreactor for commercial 
purposes (Jackson et al., 2010). Furthermore, the rapid 
transmission of the transgenic goat characteristics to
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offspring is indispensable for obtaining a transgenic 
herd to increase the availability of this recombinant 
protein and meet market demand. Thus, this study was 
divided into two experiments with one general aim 
each: i) to monitor the estrous cycles of the transgenic 
female by progesteronemia and ovarian activity 
evaluation and ii) to perform the Multiple Ovulation and 
Embryo Transfer (MOET) to quickly obtain the 
offspring of the transgenic founder female. 
 
Materials and Methods 
 
Animal ethics and biosafety 
 
The Committees of Animal Ethics (09144595-
7/50) and Biosafety (003/2010) of the State University 
of Ceará approved all protocols used in this study. 
Furthermore, goats were treated according to the 
guidelines for the ethical use of animals in research 
(Association for the Study of Animal Behaviour - 
ASAB, 2006). 
 
Animals, experimental area and management 
 
Two Canindé female goats were used in this 
experiment: a hG-CSF-transgenic (TF) and another, 
non-transgenic (NTF), used as a control. The two 
females were obtained from the same experiment to 
produce transgenic goats using pronuclear 
microinjection, (Freitas et al., 2012). At the beginning 
of the experiment the females were two years old and 
nulliparous and presented a body weight of 25.5 kg. The 
experiment was carried out in the Laboratory of 
Physiology and Control of Reproduction (LFCR), 
located in Fortaleza, Brazil, at 3°47’41’’S and 
38°33’26’’W, from January to March (Summer) and 
then from August to October (Spring). Female goats 
reared at this latitude are usually non-seasonal breeders, 
exhibiting recurrent estrous cycles throughout the year. 
One month before the experiment started, estrus was 
monitored daily using teaser bucks to verify the 
females’ cyclicity. All animals were raised under a 
semi-intensive system with daily morning access to a 
pasture of Tifton (Cynodon dactylon) and receiving hay 
of this grass in stalls. Water and mineralized salt were 
given ad libitum, and the diet was supplemented with 
commercial concentrate (18% crude protein).  
 
Experiment 1 
 
Estrous cycle monitoring 
 
Three consecutive and spontaneous estrous cycles 
were evaluated to monitor estrus and ovarian activity. 
Estrus was observed daily. The ovarian activity was 
verified by ultrasound, which was performed every three 
days beginning on estrus onset (day 0). Ovaries were 
observed using transrectal real-time ultrasonography 
(Falco 100, Pie-Medical, Maastricht, Netherlands) coupled 
to a 6/8 MHz linear probe. At the same time blood was 
collected by jugular venipuncture. Serum samples were 
separated by centrifugation (3,000 x g, 15 min) and stored 
at -20°C until assaying for progesterone concentration, 
which was carried out using commercially available 
chemiluminescence immunoassays with an automated 
Elecsys immunoanalyzer (Roche-Boehringer, Mannheim, 
Germany). The sensitivity of the assay was 0.03 ng/ml. 
 
Experiment 2  
 
Estrus synchronization and superovulation 
 
The two embryo donor goats (TF and NTF) 
and nine undefined breed recipients were subjected to 
estrus synchronization with the use of intravaginal 
sponges (Progespon, Syntex, Buenos Aires, Argentina) 
impregnated with 60 mg medroxyprogesterone acetate 
for 10 days. On day 8 of the progesterone treatment an 
im injection of 75 µg D-cloprostenol (Prolise, Arsa SRL, 
Buenos Aires, Argentina) was administered. Donors 
received 120 mg NIH-FSH P1 (Folltropin-V, Bioniche, 
Ontario, Canada) im divided into six doses at 12 h 
intervals (30/30; 15/15; 15/15 mg) starting 48 h before 
the sponge removal. This dose was determined in a 
previous study carried out in our laboratory (Moura et 
al., 2010). Also 48 h prior to the end of progesterone 
treatment, recipients received im injections of 300 IU of 
eCG (Novormon, Buenos Aires, Argentina). The 
sponges were removed at the time of the fifth FSH 
injection. To prevent the premature regression of 
corpora lutea (CL), flunixin meglumine (1.1 mg/kg; 
Flumedin, Jofadel, Varginha, Brazil) was administered 
twice daily for four days beginning on the third day 
after sponge removal. Estrus was detected from 12 h 
after sponge removal at 4 h intervals, and the donors 
were hand-mated at estrus onset and 24 h later.  
 
Progesterone and white blood cell analyses 
 
Blood samples were collected in intervals of 3 
or 4 days (twice weekly) by jugular veinpuncture, into 
vacuum tubes (BD Vacutainer, New Jersey, USA) with 
or without EDTA, always at the same time of the day 
(morning), from the sponge insertion (day 0) until the 
subsequent natural estrus. Blood samples without 
EDTA were processed as previously described for the 
analysis of serum progesterone. Blood samples with 
EDTA were used to determine the total white blood 
cell (WBC) count, which was performed with an 
automatic analyzer CELL-Dyn 3700 (Abbott Park, 
Illinois, USA).  
 
Embryo recovery and transfer 
 
Two in vivo embryo production sessions were 
performed within a ~7 month interval; one by surgery
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(laparotomy) and the other through a nonsurgical 
(transcervical) method. For both conditions embryo 
recovery was performed seven days after estrus. The 
ovulatory response of donors and recipients was verified 
by laparoscopy to assess the number of CL prior to 
embryo recovery and transfer, respectively. Donors and 
recipients were deprived of food and water for 24 h 
before embryo recovery and transfer. In the laparotomy 
procedure, the donors were anesthetized using 
intravenous administration of 20 mg/kg body weight of 
sodium thiopental (Thiopentax, Cristália, São Paulo, 
Brazil); anesthesia was maintained with isoflurane 
(Isoforine, Cristália, São Paulo, Brazil) via endotracheal 
intubation. 
The surgical embryo recovery was performed by 
a medial ventral incision to expose the genital tract, and at 
this moment, the CL number was recorded. A catheter 
connected to a sterile 20 ml syringe containing ﬂushing 
medium (DMPBS Flush; Nutricell, São Paulo, Brazil) 
was inserted near the uterus bifurcation. Another 
catheter was inserted in the utero-tubal junction, where the 
flushing medium was collected in 50 ml plastic tubes.  
For the transcervical embryo recovery donors 
received an im injection of 37.5 µg D-cloprostenol 12 h 
before the procedure. The females received 
acepromazine maleate im (1 mg/kg; Acepran 1%, 
Vetnil, São Paulo, Brazil). Immediately before the 
introduction of the vaginal speculum, an epidural block 
without epinephrine (2 ml/female; Lidocaine 
hydrochloride 2%, Anestésico L Pearson, Eurofarma, 
Brazil) was performed. Embryo recovery was 
performed with a circuit and catheter for small 
ruminants (Circuit/catheter to collect embryos for sheep 
and goats, Embrapa, Brasília, Brazil). A number 8 
catheter was used, with no balloon and equipped with a 
stylet to pass through the cervix. The stylet was 
removed, and the catheter was attached to the end of 
circuit. After flushing the first uterine horn with a total 
volume of 120 ml of DMPBS, the catheter was gently 
pulled back and guided to another horn with the help of 
a finger inserted into the female rectum. The second 
horn was then washed. The process was repeated until a 
total volume of 240 ml per uterine horn was collected. 
The recovered medium was examined under a 
stereomicroscope (SMZ-800, Nikon, Kawasaki, Japan) 
for embryo identification and evaluation regarding the 
stage of development and quality of the embryos 
according to the morphological criteria of the 
International Embryo Transfer Society (Stringfellow 
and Givens, 2009).  
The embryo transfer was performed by semi-
laparoscopy as described by Green et al. (2009). 
Briefly, for each recipient, 1-2 embryos recovered from 
the TF were transferred into the top of the uterine 
ipsilateral horn by semi-laparoscopy to an ovary bearing 
at least one functional CL.  
 
Pregnancy detection and offspring transgene analysis 
 
Pregnancy was detected by ultrasound 30 days 
following embryo transfer and weekly during pregnancy 
to conﬁrm progressive fetal development. The hG-CSF 
transgene was detected in skin biopsies from the ears of 
two-week-old kids using PCR amplification according 
to the method reported by Freitas et al. (2007). 
 
Analysis of data 
 
Data are presented as the mean ± SD. Due to 
the small amount of animals it was not possible to draw 
comparisons for some variables. When possible, the 
means were compared by t test and the values in 
percentages by Fisher's exact test. The significance level 
was 5%. 
 
Results 
 
Experiment 1  
 
After checking females’ cyclicity, the first 
natural estrus was defined as day 0 for monitoring 
estrous cycles. Both females showed clinical signs of 
estrus in three cycles. The mean interval between estrus 
was 20.7 ± 0.6 and 19.7 ± 0.6 days (P > 0.05) for the TF 
and NTF, respectively. 
When ultrasounds were performed, ovaries 
appeared as well-defined structures of oval shape and 
were slightly hypoechoic compared to the surrounding 
tissues. For the four observed estrus, the TF had only 
one ovulation at each estrus, whereas the NTF presented 
one, two, one and one ovulation, respectively. 
Serum progesterone concentrations during 
the three consecutive cycles are shown in Fig. 1. 
During the follicular phase (days 0 to 3 of the estrous 
cycle), progesterone concentrations were 0.5 ± 0.4 and 
0.6 ± 0.5 ng/ml (P > 0.05) for the TF and NTF, 
respectively. During the following days the 
progesteronemia remained high from day 6 to 
approximately day 18 and ranged from 5.2 to 12.2 ng/ml 
(TF) and 3.6 to 15.1 ng/ml (NTF), showing a similar 
pattern during the three estrous cycles (Fig. 1). The 
luteal phase was characterized by an average 
progesterone concentration of 8.1 ± 2.4 and 7.7 ± 3.7 ng/ml 
(P > 0.05) for the TF and NTF, respectively. 
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Figure 1. Serum progesterone concentrations during three consecutive estrous cycles in the transgenic (TF) and the 
non-transgenic female (NTF). The day of the first estrus for both females is considered day 0. Black or gray arrows 
indicate the days of estrus in TF or NTF, respectively.  
 
Experiment 2  
 
After the end of superovulation treatments, 
both females responded to hormonal stimulation, 
displaying signs of estrus. The ovulation rate and 
embryo recovery data are presented in Table 1. The 
ovulation rate was similar between the TF and NTF, 
averaging 12.0 ± 1.4 and 18.0 ± 4.2 CL, respectively (P 
> 0.05). There were no cases of premature regression of 
CL in either superovulation session. 
After the first treatment for superovulation, 
embryos were collected by the surgical method (Table 1). 
This method resulted in a recovery rate of 69.2% (TF) 
or 100.0% (NTF). After recovery, the TF produced nine 
embryos (eight blastocysts and one morula), whereas 
the NTF produced 21 embryos (six blastocysts, nine 
morulae and six degenerated embryos). The second 
superovulation treatment was followed by transcervical 
recovery (Table 1). The recovery rate for this method 
was 72.7% (TF) or 86.7% (NTF). Although the females 
were nulliparous at the time of recovery, the 
transcervical collection was carried out without 
difficulty and recovered almost all medium at the end of 
the procedure. Thus, the TF yielded eight embryos (six 
blastocysts, one morula and one degenerated embryo), 
and the NTF yielded 13 embryos (one blastocyst, eleven 
morulae and one degenerated embryo). There were no 
significant differences between embryo recovery 
methods. In both superovulation treatments the 
fertilization rate was 100% for T and NT females. 
 
Table 1. Parameters for surgical and transcervical embryo recovery in the transgenic (TF) and the non-transgenic 
female (NTF). 
Parameter Surgical Transcervical 
TF NTF TF NTF 
Number of flushings 1 1 1 1 
Number of ovulations 13 21 11 15 
Embryos recovered 9 21 8 13 
Recovery rate (%) 69.2a 100.0a 72.7a 86.7a 
aThe comparisons were made between recovery methods for each experimental female (P > 0.05). 
 
Regarding serum progesterone concentrations, 
an expected profile before and after hormonal treatment 
was observed (Fig. 2). In the first and second hormonal 
treatments, no functional CL was present upon the 
insertion of the sponge, as verified by the concentrations 
of progesterone. Just before embryo recovery, for 
surgical or transcervical, the progesterone concentrations 
were elevated for TF (13.5 and 16.0 ng/ml) and NTF 
(18.9 and 37.0 ng/ml), respectively. These progesterone 
values were followed by a sharp decrease in response to 
the luteolytic injection. 
The leukocyte profile was similar for both
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MOET, and thus the results are presented as an average. 
The NTF remained within the normal range for goat 
species (4 to 13 x 106/ml) before, during and after 
MOET, averaging 9.1 ± 2.4 x 106/ml from day 0 up to 
day 44. Conversely, the opposite was observed for the 
TF, which demonstrated a permanent leukocytosis, 
averaging 45.5 ± 13.9 x 106/ml throughout the 
experimental period. Regarding each step, the TF had 
~37.2 x 106/ml on days 0, 2 and 5 (before FSH 
stimulation), ~42.8 x 106/ml on days 9, 12 and 16 
(during FSH stimulation), ~49.6 x 106/ml on days 19 
up to 44 (after MOET was performed). It is important 
to highlight that the leukocytosis was due to a 
neutrophilia whereas the other cell counts were 
within the normal range for goats. The NTF had 
~44.2% (surgical MOET) and 51.0% (transcervical 
MOET) of relative neutrophil counts from days 0 to 
44 whereas the TF had 80.7% (surgical MOET) and 
80.0% (transcervical MOET) of these cells in the same 
period.  
Approximately eight days after both embryo 
recoveries the TF had at least one functional CL, 
indicated by progesteronemia higher than 1 ng/ml. 
Interestingly the NTF neither showed estrus nor 
ovulation after both embryo recoveries. 
Hormonal treatment synchronized estrus and 
induced ovulation in all recipients, producing an 
average ovulation rate of 2.4 ± 1.5 CL. All embryos 
collected from the NTF were vitrified whereas the ones 
collected from the TF were transferred to recipient 
goats. The pregnancy rate at 30 days after embryo 
transfer was 77.8% (7/9). However, the kidding rate was 
55.5% (5/9), with the birth of eight kids (four males and 
four females). These offspring included three with the 
hG-CSF transgene (two males and one female), leading 
to a transgenic rate of 37.5%. 
 
 
Figure 2. Serum progesterone concentrations before and after surgical (A) and transcervical (B) embryo recovery in 
the transgenic (TF) and the non-transgenic female (NTF). The day of sponge insertion was considered day 0. 
 
Discussion 
 
Due to latitude, both females showed the cyclic 
activity expected for goats raised near the equator. 
Whereas the average duration of the goat estrous cycle 
is 21 days, its length is highly variable. A study with 
Alpine goats during the breeding season recorded 77% 
cycles of normal duration, 14% short and 9% of long 
cycles (Baril et al., 1993). However, in the present 
work, at the end of three successive cycles, this 
variability was not detected, with goats showing estrus 
from 19 to 21 days.  
The follicular phase of the estrous cycle 
corresponds to the wave of follicle development that 
culminates in the selection of the ovulatory follicle, and 
it involves the maturation of gonadotropin-dependent 
follicles until ovulation. Approximately five days after 
the onset of estrus, cells from the ovulating follicle turn 
into luteal cells and form the CL. They secrete 
progesterone, inducing its increase and remaining at 
high concentrations (>1 ng/ml) for 16 days (reviewed by 
Fatet et al., 2011). In our experimental animals, the 
pattern and levels of increase in progesterone 
concentration and then its decline after the luteal phase 
were similar to those found in other goat breeds (Leyva-
Ocaris et al., 1995; Khanum et al., 2008). Ko et al. 
(2000) also obtained a hG-CSF–transgenic goat, which 
grew without any health problems, became sexually 
mature and exhibited a normal estrous cycle.  
Concerning the second experiment, the 
ovulation rate verified after the superovulatory 
treatment is in agreement with previous results by our 
group in Canindé goats (Moura et al., 2010). In goats, 
the use of hormonal superovulatory treatments has been 
correlated with early regression of the CL (Pintado et 
al., 1998; Saharrea et al., 1998). However, this was not 
observed in the present study, probably due to the use of 
an anti-prostaglandin agent. In both hormonal 
treatments an increase in serum progesterone on day 16 
after the start of the hormonal treatment was noticed, 
consistent with the superovulatory response. The level 
of progesterone is correlated with the number of CL 
(Jarrell and Diziuk, 1991). One day after embryo 
recovery, progesterone decreased (< 1 ng/ml) due to the 
luteolytic action.  
Regarding the white blood cell analysis, the TF
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demonstrated a similar leukocyte profile since when she 
aged 1.5 months (Freitas et al., 2012). A leukocytosis 
was reported due to a neutrophilia although the other 
granulocytic and non-granulocytic cell counts were 
within the normal range for goat species (Pugh, 2002). 
This is expectable since the TF has a transgene 
associated to increase of neutrophils. It is noteworthy 
that the pattern was not affected before, during or after 
MOET and that the doe remained healthy throughout 
the whole experimental period. 
Quickly generating transgenic progeny from a 
transgenic founder goat can be achieved by several 
techniques, including MOET, in vitro fertilization 
(IVF), and somatic cell nuclear transfer (SCNT). The 
use of MOET may be more practical than IVF or SCNT. 
However, animal care organizations around the world 
are enforcing regulations that limit the number of 
surgical procedures that can be performed per animal 
ranging between one and four (Baldassarre et al., 2003). 
Therefore, the use of less invasive recovery techniques 
is preferential. Additionally, they avoid causing 
adhesions (such as those induced by the surgical 
method), may allow the use of successive embryo 
recoveries in donors (Suyadi and Holtz, 2000). In this 
study, the methods of embryo recovery did not affect 
the recovery rate in both females. Souza et al. (2008), 
also working with a naturalized breed from northeastern 
Brazil, observed a recovery rate of 80% after surgical 
embryo recovery. Considering the inestimable value of 
the TF, we decided to use a less invasive approach for 
embryo collection. Both females were nulliparous and 
of a small size breed. The transcervical method 
minimized the trauma to the female, making it possible 
to recover a high number of embryos per donor, 
considering the potential of its use in several 
collections.  
It was confirmed that our transgenic goat is a 
true founder since she was able to produce transgenic 
offspring. As our TF was obtained by pronuclear 
microinjection, we expected the transgene to be 
inherited by 50% of the offspring. The production of 
the F1 generation of this line apparently transmitted 
the hG-CSF transgene in a Mendelian fashion, 
presuming they were hemizygous for the transgene. 
Melican and Gavin (2008) also used superovulation 
coupled with embryo transfer to accelerate the 
production of transgenic progeny from a founder dairy 
goat. Those authors observed a transgenesis rate of 
26%, which was slightly lower than that observed in 
our study. 
In conclusion, the hG-CSF–transgenic female 
founder presented estrous cycles and a progesterone 
profile which were normal and regular. Additionally, 
this goat is a true founder, since it is fertile and 
capable of transmitting the hG-CSF transgene to 
progeny by MOET. Therefore, the analyzed 
reproductive traits were not compromised due to the 
presence of the transgene. 
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